GLI1 is a key effector in the HH pathway37,38, and its overexpression confirmed that the HH pathway is activated in HCC, contributing to drug resistance by maintaining stem-like properties, the onset of epithelial–mesenchymal transition and the induction of ABC transporters in HCC16. This evidence concerns the gene GLI1 and hepatocellular carcinoma.